From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
(-)-Fucose is classified as a member of the hexoses, plays a role in A and B blood group antigen substructure determination, selectin-mediated leukocyte-endothelial adhesion, and host-microbe interactions. (-)-Fucose is orally active, inhibits CL11-induced inflammatory response in kidney and tumor growth .
(-)-Fucose (Standard) is the analytical standard of (-)-Fucose. This product is intended for research and analytical applications. (-)-Fucose is classified as a member of the hexoses, plays a role in A and B blood group antigen substructure determination, selectin-mediated leukocyte-endothelial adhesion, and host-microbe interactions. (-)-Fucose is orally active, inhibits CL11-induced inflammatory response in kidney and tumor growth .
GDP-L-fucose is a nucleotide sugar that is a key substrate for the biosynthesis of fucose oligosaccharides, providing the fucose moiety for the oligosaccharides.The formation of GDP-L-fucose occurs through two pathways, the major ab initio metabolic pathway and the minor remedial metabolic pathway. GDP-L-fucose is associated with diabetes in rats .
GDP-L-fucose disodium is a nucleotide sugar that is a key substrate for the biosynthesis of fucose oligosaccharides. GDP-L-fucose disodium provides the fucose moiety for the oligosaccharides. The formation of GDP-L-fucose disodium occurs through two pathways, the major de novo metabolic pathway and the minor remedial metabolic pathway .
2-Deoxy-2-fluoro-L-fucose, an L-fucose analog, is a fucosylation inhibitor. 2-Deoxy-2-fluoro-L-fucose inhibits de novo synthesis of GDP-fucose in mammalian cells. Fucosylation is a relatively well-defined biomarker for progression in many human cancers; for example, pancreatic and hepatocellular carcinoma .
(-)-Fucose- 13C is the 13C labeled (-)-Fucose. (-)-Fucose is classified as a member of the hexoses, plays a role in A and B blood group antigen substructure determination, selectin-mediated leukocyte-endothelial adhesion, and host-microbe interacti[1]
(-)-Fucose- 13C-2 is the 13C labeled (-)-Fucose. (-)-Fucose is classified as a member of the hexoses, plays a role in A and B blood group antigen substructure determination, selectin-mediated leukocyte-endothelial adhesion, and host-microbe interacti[
(-)-Fucose- 13C-3 is the 13C labeled (-)-Fucose. (-)-Fucose is classified as a member of the hexoses, plays a role in A and B blood group antigen substructure determination, selectin-mediated leukocyte-endothelial adhesion, and host-microbe interacti[
(-)-Fucose- 13C-1 is the 13C labeled (-)-Fucose. (-)-Fucose is classified as a member of the hexoses, plays a role in A and B blood group antigen substructure determination, selectin-mediated leukocyte-endothelial adhesion, and host-microbe interacti[
GDP-Fucose-Tz (GDP-Fucose-Am-Tz) is a click chemistry reagent, it contains a Tetrazine group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing TCO groups. GDP-fucose-Am-Tz and TCO-ssDNA were reacted at a ratio of 1:1 to obtain the final product GDP-fucose-ssDNA .
D-(+)-Fucose (Standard) is the analytical standard of D-(+)-Fucose. This product is intended for research and analytical applications. D-(+)-Fucose is a nonmetabolizable analogue of l-arabinose. D-(+)-Fucose prevents growth of Escherichia coli B/r on a mineral salts medium plus l-arabinose by inhibiting induction of the l-arabinose operon . D-fucose is a potent inducer of beta-methylgalactoside permease (MGP) .
D-(+)-Fucose is a nonmetabolizable analogue of l-arabinose. D-(+)-Fucose prevents growth of Escherichia coli B/r on a mineral salts medium plus l-arabinose by inhibiting induction of the l-arabinose operon . D-fucose is a potent inducer of beta-methylgalactoside permease (MGP) .
L-fucokinase/GDP-fucose pyrophos-phorylase (FKP) is an enzyme that catalyzes the chemical reaction. L-fucokinase/GDP-fucose pyrophos-phorylase (FKP) has substrate of L-fucose. L-fucokinase/GDP-fucose pyrophos-phorylase (FKP) induces L-fucose phosphorylation to form L-fucose-L-phosphate .
6-Alkynyl fucose is a tool in the study of protein O-fucosylation . 6-Alkynyl fucose is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
α1-2,4,6 Fucosidase O (EC 3.2.1.51) is a broad specificity exoglycosidase that catalyzes the hydrolysis of terminal α1-2, α1-4 and α1-6 linked fucose residues from oligosaccharides, with α1-6 fucose residues more efficiently .
α1-2 Fucosidase (EC 3.2.1.51) is a highly specific exoglycosidase that catalyzes the hydrolysis of linear α1-2 linked fucose residues from oligosaccharides .
α1-3,4 Fucosidase, Bifidobacterium bifidum is a broad specificity exoglycosidase that catalyzes the hydrolysis of terminal, non-reducing α1-3 and α1-4 linked fucose residues from oligosaccharides and glycoproteins .
Fucosyltransferase 8 (EC:2.4.1.68; FUT8; α1-6FucT) is a glycosyl transferase and catalyzes the transfer of a fucose residue from GDP-fucose to the innermost N-acetylglucosamine residue of N-glycans .
Lactodifucotetraose (Difucosyllactose) is a tetrasaccharide isolated from human milk. Lactodifucotetraose constitutes of D-glucose, 1 D-galactose, and L-fucose .
Bemarituzumab (FUT8-KO) is an anti-FGFR2b monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Bemarituzumab (FUT8-KO) lacks a core fucose in the polysaccharide portion of the Fc domain of the antibody, and results in a high affinity to human FcγRIIIa .
alpha-1,3-Fucosyltransferase (α1,3FucT) catalyzes the transfer of L-fucose moiety from guanosine diphosphate-beta-L-fucose (GDP-Fuc) to acceptor sugars. alpha-1,3-Fucosyltransferase (α1,3FucT) is often used in biochemical studies, and it can be used to form fucoglycoconjugates .
Protein O-Fucosyltransferase 1 (EC:2.4.1.221; POFUT1) is a Glycosyltransferase containing the cysteine-rich motifs as the acceptor sugar and GDP-fucose as the donor .
alpha-1,3/4-Fucosyltransferase (α1,3/4FucT) (EC 2.4.1.65) (Hp3/4FT) can be found in Helicobacter pylori. alpha-1,3/4-Fucosyltransferase (α1,3/4FucT) catalyzes fucose transfer from donor GDP-beta-l-fucose to the GlcNAc .
Fucosyltransferase 11 (EC:2.4.1.-, FUT11) links alpha-l-fucose onto conalbumin glycopeptides and biantennary N-glycan acceptors. Fucosyltransferase 11 plays an important role in cancer .
Fucosyltransferase 9 (EC:2.4.1.152, FUT9) catalyzes the last step in the biosynthesis of Lewis antigen, the addition of a fucose to precursor polysaccharides. Fucosyltransferase 9 synthesizes the LeX oligosaccharide (CD15) .
GDP-α-D-mannose disodium is the donor substrate for mannosyltransferases and the precursor of GDP-β-L-fucose. GDP-α-D-mannose disodium gives a competitive inhibition with respect to GTP (Ki 14.7 μM) and an uncompetitive inhibition with respect to mannose-1-P (Ki 115 μM) .
Lotus tetragonolobus lectin (LTL) is a plant lectin, that can be extracted from Lotus tetragonolobus. Lotus tetragonolobus lectin recognizes and binds to fucose containing sugar structures, and can be used to study cell surface receptor recognition and cell adhesion processes. Lotus tetragonolobus lectin inhibits macrophage migration, and is involved in immunomodulatory processes .
Belantamab (FUT-8 KO) is an anti-BCMA (TNFRSF17) monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Belantamab (FUT-8 KO) can be used to synthesize antibody-active molecule conjugate (ADC), Belantamab mafodotin .
Ianalumab (FUT8-KO) is an anti-BAFF-R monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Ianalumab (FUT8-KO) can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF .
Osemitamab (FUT8-KO) is an anti-claudin-18.2 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
GDP-D-mannose disodium contains GDP-α-D-mannose (HY-N7389B) and GDP-β-D-mannose. GDP-α-D-mannose is the donor substrate for mannosyltransferases and the precursor of GDP-β-L-fucose. GDP-α-D-mannose gives a competitive inhibition with respect to GTP (Ki 14.7 μM) and an uncompetitive inhibition with respect to mannose-1-P (Ki 115 μM) .
Amivantamab (FUT8-KO) is an anti-EGFR-MET monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Amivantamab (FUT8-KO) inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .
Inebilizumab (FUT8-KO) is an anti-CD19 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Inebilizumab (HY-P99113) is a monoclonal antibody (mAb) targeting CD19, exhibiting enhanced antibody-dependent cellular cytotoxicity (ADCC) against B cells. Inebilizumab can be used for research on multiple sclerosis and neuromyelitis optica .
Petosemtamab (FUT8-KO) is an anti-EGFR/LGR5 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Petosemtamab (HY-P99406) is an anti-EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to blockade of EGFR signaling and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the study of solid tumors such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC), etc .
GDP-L-fucose disodium is a nucleotide sugar that is a key substrate for the biosynthesis of fucose oligosaccharides. GDP-L-fucose disodium provides the fucose moiety for the oligosaccharides. The formation of GDP-L-fucose disodium occurs through two pathways, the major de novo metabolic pathway and the minor remedial metabolic pathway .
Fucosyltransferase 8 (EC:2.4.1.68; FUT8; α1-6FucT) is a glycosyl transferase and catalyzes the transfer of a fucose residue from GDP-fucose to the innermost N-acetylglucosamine residue of N-glycans .
Protein O-Fucosyltransferase 1 (EC:2.4.1.221; POFUT1) is a Glycosyltransferase containing the cysteine-rich motifs as the acceptor sugar and GDP-fucose as the donor .
Fucosyltransferase 11 (EC:2.4.1.-, FUT11) links alpha-l-fucose onto conalbumin glycopeptides and biantennary N-glycan acceptors. Fucosyltransferase 11 plays an important role in cancer .
Fucosyltransferase 9 (EC:2.4.1.152, FUT9) catalyzes the last step in the biosynthesis of Lewis antigen, the addition of a fucose to precursor polysaccharides. Fucosyltransferase 9 synthesizes the LeX oligosaccharide (CD15) .
Lotus tetragonolobus lectin (LTL) is a plant lectin, that can be extracted from Lotus tetragonolobus. Lotus tetragonolobus lectin recognizes and binds to fucose containing sugar structures, and can be used to study cell surface receptor recognition and cell adhesion processes. Lotus tetragonolobus lectin inhibits macrophage migration, and is involved in immunomodulatory processes .
Inebilizumab (FUT8-KO) is an anti-CD19 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Inebilizumab (HY-P99113) is a monoclonal antibody (mAb) targeting CD19, exhibiting enhanced antibody-dependent cellular cytotoxicity (ADCC) against B cells. Inebilizumab can be used for research on multiple sclerosis and neuromyelitis optica .
Bemarituzumab (FUT8-KO) is an anti-FGFR2b monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Bemarituzumab (FUT8-KO) lacks a core fucose in the polysaccharide portion of the Fc domain of the antibody, and results in a high affinity to human FcγRIIIa .
Belantamab (FUT-8 KO) is an anti-BCMA (TNFRSF17) monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Belantamab (FUT-8 KO) can be used to synthesize antibody-active molecule conjugate (ADC), Belantamab mafodotin .
Ianalumab (FUT8-KO) is an anti-BAFF-R monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Ianalumab (FUT8-KO) can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF .
Osemitamab (FUT8-KO) is an anti-claudin-18.2 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
Amivantamab (FUT8-KO) is an anti-EGFR-MET monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Amivantamab (FUT8-KO) inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .
Petosemtamab (FUT8-KO) is an anti-EGFR/LGR5 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Petosemtamab (HY-P99406) is an anti-EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to blockade of EGFR signaling and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the study of solid tumors such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC), etc .
(-)-Fucose is classified as a member of the hexoses, plays a role in A and B blood group antigen substructure determination, selectin-mediated leukocyte-endothelial adhesion, and host-microbe interactions. (-)-Fucose is orally active, inhibits CL11-induced inflammatory response in kidney and tumor growth .
(-)-Fucose (Standard) is the analytical standard of (-)-Fucose. This product is intended for research and analytical applications. (-)-Fucose is classified as a member of the hexoses, plays a role in A and B blood group antigen substructure determination, selectin-mediated leukocyte-endothelial adhesion, and host-microbe interactions. (-)-Fucose is orally active, inhibits CL11-induced inflammatory response in kidney and tumor growth .
GDP-L-fucose is a nucleotide sugar that is a key substrate for the biosynthesis of fucose oligosaccharides, providing the fucose moiety for the oligosaccharides.The formation of GDP-L-fucose occurs through two pathways, the major ab initio metabolic pathway and the minor remedial metabolic pathway. GDP-L-fucose is associated with diabetes in rats .
GDP-L-fucose disodium is a nucleotide sugar that is a key substrate for the biosynthesis of fucose oligosaccharides. GDP-L-fucose disodium provides the fucose moiety for the oligosaccharides. The formation of GDP-L-fucose disodium occurs through two pathways, the major de novo metabolic pathway and the minor remedial metabolic pathway .
D-(+)-Fucose is a nonmetabolizable analogue of l-arabinose. D-(+)-Fucose prevents growth of Escherichia coli B/r on a mineral salts medium plus l-arabinose by inhibiting induction of the l-arabinose operon . D-fucose is a potent inducer of beta-methylgalactoside permease (MGP) .
Lactodifucotetraose (Difucosyllactose) is a tetrasaccharide isolated from human milk. Lactodifucotetraose constitutes of D-glucose, 1 D-galactose, and L-fucose .
GDP-α-D-mannose disodium is the donor substrate for mannosyltransferases and the precursor of GDP-β-L-fucose. GDP-α-D-mannose disodium gives a competitive inhibition with respect to GTP (Ki 14.7 μM) and an uncompetitive inhibition with respect to mannose-1-P (Ki 115 μM) .
GDP-D-mannose disodium contains GDP-α-D-mannose (HY-N7389B) and GDP-β-D-mannose. GDP-α-D-mannose is the donor substrate for mannosyltransferases and the precursor of GDP-β-L-fucose. GDP-α-D-mannose gives a competitive inhibition with respect to GTP (Ki 14.7 μM) and an uncompetitive inhibition with respect to mannose-1-P (Ki 115 μM) .
D-(+)-Fucose (Standard) is the analytical standard of D-(+)-Fucose. This product is intended for research and analytical applications. D-(+)-Fucose is a nonmetabolizable analogue of l-arabinose. D-(+)-Fucose prevents growth of Escherichia coli B/r on a mineral salts medium plus l-arabinose by inhibiting induction of the l-arabinose operon . D-fucose is a potent inducer of beta-methylgalactoside permease (MGP) .
The FUOM/fucose mutarotase protein has a crucial interconversion effect on α- and β-L-fucose, with β-L-fucose being dominant (70.5%). The β-form undergoes metabolic processes via the salvage pathway, producing GDP-L-fucose that is transported to the endoplasmic reticulum. FUOM/Fucose Mutarotase Protein, Human (His) is the recombinant human-derived FUOM/Fucose Mutarotase protein, expressed by E. coli , with N-His labeled tag.
Dai protein serves as a catalyst in the biochemical conversion of the aldose L-fucose into its corresponding ketose, L-fuculose. This enzymatic activity highlights Dai's role in facilitating the transformation of specific sugar molecules, contributing to the diverse metabolic pathways where such conversions play essential roles. dai Protein, Aeribacillus pallidus is the recombinant dai protein, expressed by E. coli , with tag free. The total length of dai Protein, Aeribacillus pallidus is 595 a.a., .
Dai protein serves as a catalyst in the biochemical conversion of the aldose L-fucose into its corresponding ketose, L-fuculose. This enzymatic activity highlights Dai's role in facilitating the transformation of specific sugar molecules, contributing to the diverse metabolic pathways where such conversions play essential roles. dai Protein, Aeribacillus pallidus (FLAG, His) is the recombinant dai protein, expressed by E. coli , with N-6*His, N-Flag labeled tag. The total length of dai Protein, Aeribacillus pallidus (FLAG, His) is 595 a.a., .
GDP-L-Fucose Synthase; GDP-4-Keto-6-Deoxy-D-Mannose-3; 5-Epimerase-4-Reductase; Protein FX; Red Cell NADP(H)-Binding Protein; Short-Chain Dehydrogenase/Reductase Family 4E Member 1; TSTA3; SDR4E1
The TSTA3 protein plays a key role in catalyzing the two-step NADP-dependent conversion of GDP-4-dehydro-6-deoxy-D-mannose to GDP-fucose. The process involves successive epimerase and reductase reactions, ultimately leading to the biosynthesis of GDP-fucose. TSTA3 Protein, Human (His) is the recombinant human-derived TSTA3 protein, expressed by E. coli , with C-6*His labeled tag. The total length of TSTA3 Protein, Human (His) is 321 a.a., with molecular weight of ~40.0 kDa.
(-)-Fucose- 13C is the 13C labeled (-)-Fucose. (-)-Fucose is classified as a member of the hexoses, plays a role in A and B blood group antigen substructure determination, selectin-mediated leukocyte-endothelial adhesion, and host-microbe interacti[1]
(-)-Fucose- 13C-2 is the 13C labeled (-)-Fucose. (-)-Fucose is classified as a member of the hexoses, plays a role in A and B blood group antigen substructure determination, selectin-mediated leukocyte-endothelial adhesion, and host-microbe interacti[
(-)-Fucose- 13C-3 is the 13C labeled (-)-Fucose. (-)-Fucose is classified as a member of the hexoses, plays a role in A and B blood group antigen substructure determination, selectin-mediated leukocyte-endothelial adhesion, and host-microbe interacti[
(-)-Fucose- 13C-1 is the 13C labeled (-)-Fucose. (-)-Fucose is classified as a member of the hexoses, plays a role in A and B blood group antigen substructure determination, selectin-mediated leukocyte-endothelial adhesion, and host-microbe interacti[
6-Alkynyl fucose is a tool in the study of protein O-fucosylation . 6-Alkynyl fucose is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
GDP-Fucose-Tz (GDP-Fucose-Am-Tz) is a click chemistry reagent, it contains a Tetrazine group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing TCO groups. GDP-fucose-Am-Tz and TCO-ssDNA were reacted at a ratio of 1:1 to obtain the final product GDP-fucose-ssDNA .
Inquiry Online
Your information is safe with us. * Required Fields.
